These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 20110030

  • 1. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS, Mikkelsen S, Knudsen TK, Kappelgaard AM.
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [Abstract] [Full Text] [Related]

  • 2. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients.
    Kappelgaard AM, Mikkelsen S, Knudsen TK, Fuchs GS.
    J Pediatr Endocrinol Metab; 2011 Dec; 24(7-8):489-96. PubMed ID: 21932587
    [Abstract] [Full Text] [Related]

  • 3. Children and adolescent acceptability of a new device system to administer human growth hormone--a pilot study.
    Kappelgaard AM, Mikkelsen S, Bagger C, Fuchs GS.
    J Pediatr Endocrinol Metab; 2012 Dec; 25(3-4):285-94. PubMed ID: 22768658
    [Abstract] [Full Text] [Related]

  • 4. Assessment of user-friendliness of the Norditropin FlexPro for pediatric patients treated with recombinant human growth hormone: results of an open-label user survey.
    Adachi M.
    J Pediatr Endocrinol Metab; 2013 Dec; 26(11-12):1105-10. PubMed ID: 23843576
    [Abstract] [Full Text] [Related]

  • 5. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients.
    Pfützner A, Hartmann K, Winter F, Fuchs GS, Kappelgaard AM, Rohrer TR.
    Clin Ther; 2010 Oct; 32(11):1918-34. PubMed ID: 21095487
    [Abstract] [Full Text] [Related]

  • 6. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J, Pleil A, Deeb LC, Fuqua JS, Silverman LA, Reiner B, Newfield R, Rajicic N, Wajnrajch MP, Cara JF.
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [Abstract] [Full Text] [Related]

  • 7. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings.
    Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L.
    Clin Ther; 2013 Jul; 35(7):923-933.e4. PubMed ID: 23790553
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
    Pawlikowska-Haddal A.
    Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
    [Abstract] [Full Text] [Related]

  • 9. Norditropin SimpleXx: a liquid human growth hormone formulation, a pen system and an auto-insertion device.
    Müller J, Skakkebaek NE, Jacobsen BB, Keller E, Heinrich U, Hartmann K, Hokken-Koelega AC, Delemarre van de Waal HA.
    Horm Res; 1999 Jun; 51 Suppl 3():109-12. PubMed ID: 10592453
    [Abstract] [Full Text] [Related]

  • 10. Comparison of injection dose force, accuracy and precision among three growth hormone injection devices.
    Kappelgaard AM, Hansen NÅ.
    Expert Rev Med Devices; 2013 May; 10(3):321-7. PubMed ID: 23560872
    [Abstract] [Full Text] [Related]

  • 11. Developments in administration of growth hormone treatment: focus on Norditropin® Flexpro®.
    Yuen KC, Amin R.
    Patient Prefer Adherence; 2011 Mar 10; 5():117-24. PubMed ID: 21448295
    [Abstract] [Full Text] [Related]

  • 12. Comparison of intuitiveness, ease of use and preference among three prefilled, disposable growth hormone injection pens.
    Rohrer TR, Winter F, Qvist M, Kappelgaard AM.
    Expert Opin Drug Deliv; 2013 Dec 10; 10(12):1603-12. PubMed ID: 24073645
    [Abstract] [Full Text] [Related]

  • 13. Ease of use and patient preference injection simulation study comparing two prefilled insulin pens.
    Clark PE, Valentine V, Bodie JN, Sarwat S.
    Curr Med Res Opin; 2010 Jul 10; 26(7):1745-53. PubMed ID: 20482243
    [Abstract] [Full Text] [Related]

  • 14. An open-label acceptability study of Norditropin SimpleXx--a new liquid growth hormone formulation.
    Stanhope R, Buchanan C, Butler G, Costigan C, Dunger D, Greene S, Hoey H, Hughes I, Kelnar C, Kirk J, Komulainen J, Lowry M, Warner J.
    J Pediatr Endocrinol Metab; 2001 Jun 10; 14(6):735-40. PubMed ID: 11453523
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.
    Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM.
    Med Devices (Auckl); 2013 Jun 10; 6():107-14. PubMed ID: 23946672
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Growth hormone therapy with a new delivery system.
    Jørgensen JT, Susgaard S.
    Indian J Pediatr; 1991 Jun 10; 58 Suppl 1():43-50. PubMed ID: 1824374
    [Abstract] [Full Text] [Related]

  • 19. Patient acceptability of a new 3.0 ml pre-filled insulin pen.
    D'Eliseo P, Blaauw J, Milicević Z, Wyatt J, Ignaut DA, Malone JK.
    Curr Med Res Opin; 2000 Jun 10; 16(2):125-33. PubMed ID: 10893656
    [Abstract] [Full Text] [Related]

  • 20. Indications for growth hormone therapy in children.
    Kirk J.
    Arch Dis Child; 2012 Jan 10; 97(1):63-8. PubMed ID: 21540481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.